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Abstract
Induction of the antiproliferative and antiviral state by IFNs (type I and II) is dramatically impaired in HepG2 cells. We
show here that RNase L, IDO, GBP-2 and iNOS genes normally expressed as a secondary response to IFN are no longer
inducible in HepG2 cells, while induction of primary response genes (IRF-1, PKR, p48-ISGF3Q, 2^5AS, 6-16 and p56-
trptRNA) are unaffected. On the basis of previous data implicating transcription factor IRF-1 in the induction of some IFN-
induced genes, we tested the effects of transfecting an IRF-1 oligonucleotide antisense in HeLa cells and found specifically
impaired IFN induction of secondary response genes (RNase L, IDO and GBP-2). This raised the possibility that IRF-1 was
defective in HepG2 cells. However, some molecular and biochemical analyses reveal that IRF-1 is induced normally by IFNs
and retains its normal size, cellular location, phosphorylation status and ability to bind the IDO promoter in vitro.
Therefore, we conclude that although the primary response pathway is fully functional, some aspects of the secondary
pathway involving IRF-1 (but not IRF-1 itself) are defective in HepG2 cells. It may be possible that the promoter region of
these deficient HepG2-genes requires an unidentified transcription factor in addition to de novo IRF-1, which could be
elicited by a cooperative activator. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The pleiotropic e¡ects of interferons (IFNs) are
mediated by constitutive and inducible signaling
JAK^STAT pathways in various cell types [1]. This
machinery is under stringent control since these path-
ways are responsible for the expression of genes im-
portant for antiviral state, cell growth and di¡eren-
tiation [2]. The induction of the IFN-stimulated
genes (ISGs) is regulated at the transcriptional level,
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but the mechanisms of induction by type I or II IFN
are distinct. These two IFN types induce overlapping
sets of target genes through independent cell surface
receptors and distinct JAK^STAT pathways [1,3,4].
Type I IFN activates Janus tyrosine kinases tyk2
and JAK1 which in turn phosphorylate cytoplasmic
STAT1 and STAT2 proteins that migrate to the nu-
cleus. These factors, together with p48, form a tri-
meric transcriptional complex termed ISGF3, which
binds to DNA at the IFN-stimulated response ele-
ment (ISRE) whose consensus sequence is A/
GNGAAANNGAAACT [5]. Similarly, type II IFN
activates the dimerization of STAT1 to form the
transcription factor GAF (IFN-Q activating factor)
which bind to a distinct cis-element, termed GAS
(Q-IFN-activated site) to activate gene transcription
[6,7]. These events occur within minutes of receptor
occupancy without requiring new protein synthesis,
and are down-regulated within a few hours of the
initial stimulus [1]. Although some ISGs are depend-
ent on ISGF3 or GAF for their immediate transcrip-
tional induction, others, such as iNOS, GBP and
CIITA, require protein synthesis and are expressed
as a secondary response pathway [8^10].
Both IFN types induce a transactivator, termed
IRF-1, that has been found to act as a master regu-
lator of some type I and II stimulated genes. But
interestingly, the IRF-1 DNA binding site, termed
ISRE-like or IRF-element (IRF-E) (G(A)AAAG/C
T/CGAAAG/C T/C) overlaps the ISRE canonical con-
sensus sequence [11]. However, this IRF-E di¡ers
from the consensus ISRE in that it does not form
a stable complex in vitro with the IFN-activated fac-
tor ISGF3, which mediates type I IFN-inducible
gene expression [12].
Our current understanding of the mechanisms of
IFN-stimulated genes results to a large extend from
mice having a de¢cient target gene and from the
study of various mutant cell lines a¡ected in certain
essential regulatory factors. We have shown previ-
ously that human hepatoma HepG2 cells were im-
paired by a speci¢c defect in RNase L expression,
since 2^5A synthetase was normally expressed [13].
In the present study, we demonstrate that HepG2
cells do not exhibit signi¢cant antiproliferative or
antiviral responses to either type I or II interferon.
This led us to examine the ability of IFNs to increase
the mRNA levels of some target genes, particularly
those implicated in the antiviral and antigrowth IFN
pathways. We demonstrate that primary induced
gene expression is una¡ected while secondary re-
sponse is completely impaired. IRF-1 function was
analyzed by examining the e¡ect of an IRF-1 oligo-
nucleotide antisense in type II IFN-treated HeLa
cells and we found that IFN induction of secondary
response genes (RNase L, IDO, GBP-2) was specif-
ically impaired. However, IRF-1 in HepG2 cells is
induced normally and is fully functional as shown
by its ability to bind the IDO promoter in vitro.
Taken together, these observations demonstrate
that the secondary pathway involving IRF-1, but
not IRF-1 itself, is defective in HepG2 cells. This
gives new insights and suggests that a more complex
level of regulation for these IFN-induced genes may
be involved, probably including the requirement for
an additional cooperative transcription factor which
is missing in HepG2 cells.
2. Materials and methods
2.1. Cells and reagents
HeLa (human epithelioid carcinoma, cervix),
HepG2 (human hepatoma) and L929 mouse ¢bro-
blast cells (from the American Type Culture Collec-
tion) were grown and maintained in RPMI 1640 me-
dium supplemented with 5% (v/v) fetal calf serum, 50
IU/ml penicillin, 10 mM glutamine and 50 Wg/ml
streptomycin. Vesicular stomatitis virus (VSV; Indi-
ana strain) and encephalomyocarditis virus (EMCV)
were grown in L929 cell monolayers and titrated by
dilution plaque assay.
Cells were treated with IFN for various periods up
to 5 days and labeled with [3H]thymidine (1 WCi/ml).
At intervals, cells were counted and DNA was pre-
cipitated with 10% (v/v) cold trichloroacetic acid for
1 h, washed with 5% (v/v) trichloroacetic acid and
collected on glass ¢ber ¢lters (Whatman GF/C). The
¢lters were washed and the radioactivity counted in
scintillation liquid.
Type I interferon (106 IU/ml) was obtained from
Me¤rieux Institut, France and type II interferon (105
IU/ml) was obtained from Boehringer. The cationic
lipid DOTMA (lipofectin) was purchased from Gib-
co-Bethesda Research Laboratories. Oligonucleotides
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were synthesized by Genosys. Polyclonal antibodies
against human IRF-1 and STAT-1 proteins were ob-
tained from Santa Cruz Biotechnologies. Goat poly-
clonal antibodies linked to horseradish peroxidase,
superscript reverse transcriptase and Taq polymerase
were obtained from Life Technology Inc. Polynu-
cleotide kinase was obtained from Pharmacia. [Q-
32P]ATP (speci¢c activity 3000 Ci/mM) and [meth-
yl-3H]thymidine (speci¢c activity 64 Ci/mM) were
purchased from Amersham and ICN.
2.2. Reverse transcription (RT)
Reverse transcription was carried out using Life
Technologies kit according to the manufacturer’s in-
struction. Total RNA (10 Wg) was denatured at 70‡C
for 5 min and reverse transcribed with 5 pmol of
each antisense primer at 37‡C for 60 min in 20 Wl
of reaction solution containing 50 mM Tris-HCl, pH
8.3, 40 mM KCl, 1 mM DTT, 6 mM MgCl2, 0.5 mM
dNTPs, 0.8 U of superscript II RNase H3 reverse
transcriptase. Antisense primers were speci¢c to
RNase L: 5P-TGC ATC CAG TGC CCA GAC
TTA-3P (2922^2902); indoleamine 2,3-dioxygenase
(IDO): 5P-GAG CTT TCC ACA CAG GCG TCA
TAA-3P (1605^1582); guanylate binding protein iso-
form 2 (GBP-2), 5P-ACT GCT GGT CAT CTG
GAA GAA TA-3P (2246^2224); nitric oxide synthase
(iNOS), 5P-CCA AAG ATA TCT TCG TGA TAG
CGC-3P (3610^3587); 6-16, 5P-GCT GCA GTG
TAC TAT GTT CGC ATC-3P (6553^6530); interfer-
on regulatory factor-1 (IRF-1), 5P-CAC GGT TCT
CAG AAC CTC ATC TT-3P (1419^1397); protein
kinase dsRNA-dependent (PKR), 5P-GAT GAT
GCC ATC CCG TAG GTC-3P (1695^1675); p48
ISGF3Q, 5P-TTT CAG GAC ACG ATT ATC
ACG GA-3P (1350^1328); p69 2^5A synthetase, 5P-
GGA AGA AAA TTT GCG GAT GA-3P (2567^
2548); p56 trptRNA synthetase, 5P-AGT GGC
TGA TAT CTG GGT GCC-3P (1521^1501). The
reaction was stopped by heating at 90‡C for 3 min
and was then used as the cDNA solution. cDNA
samples were stored at 320‡C until polymerase chain
reaction (PCR) analysis.
2.3. PCR analysis
One-tenth of the ¢rst strand of cDNA synthesized
was used for 40 cycles of PCR ampli¢cation of
RNase L, IDO, GBP-2, iNOS, 6-16, IRF-1, PKR,
p48 ISGF3Q, p69 2^5A synthetase, p56 trptRNA syn-
thetase and L-actin for control. The PCR cycles in-
cluded 40 s of denaturation at 94‡C, 40 s of anneal-
ing at 58‡C, and 60 s/kb of extension at 72‡C, using a
Biometra PCR apparatus. The following primer pairs
(from Genosys), based on the cDNA sequence, were
used to amplify mRNA sequences: primers speci¢c
to RNase L were 1596-bp sense, 5P-GCT CAC CTG
GCA GAT TTT GAT AA-3P ; and 2874-bp anti-
sense, 5P-AAT GAA TGA GAT TCC TGG AAC
C-3P (the fragment was 1278 bp); for IDO, primers
were 1635-bp sense, 5P-CAA GAA TGG CAC ACG
CTA TGG; and 1605-bp antisense, 5P-TGA AAG
GAC AAA CTC ACG GA-3P (the fragment was
970 bp); for GBP-2, primers were 368-bp sense, 5P-
GTC TGG GAG ATG TAG AGA AGG GT-3P ;
and 1963-bp antisense, 5P-GGC TCT GGT CTT
TAG CTT ATG GT-3P (the fragment was 1595
bp); for iNOS, the primers were 904-bp sense, 5P-
ATC TGC AGA CAC GTG CGT TAC TC; and
2103-bp antisense, 5P-GAG GCC AAA CAC AGA
GTA GGT-3P (the fragment was 1199 bp); for 6-16,
the primers were 59-bp sense, 5P-TCT TCT CTC
CTC CAA GTC TAG TGT GAC G-3P ; and 493-
bp antisense, 5P-ACT CCT CAT CCT CCT CAC
TAT CGA G-3P (the fragment was 434 bp); for
IRF-1, the primers were 66-bp sense, 5P-TTA AGA
ACC AGG CAA CCT CTG-3P ; and 1447-bp anti-
sense, 5P-TAC ACC ACA AGA AAA ACC CA-3P
(the fragment was 1381 bp); for PKR, the primers
were 154-bp sense, 5P-ACA AAG CTT CCA ACC
AGG ATA CG-3P ; and 1621-bp antisense, 5P-CAA
GAA TTA GCC CCA AAG CGT AG-3P (the frag-
ment was 1467 bp); for p48 ISGF3Q, the primers
were 128-bp sense, 5P-GAT ACA GCT AAG ACC
ATG TTC CGG-3P ; and 1310-bp antisense, 5P-ACA
AAG AGG ACA GGT CAA TGC-3P (the fragment
was 1182 bp); for p69 2^5A synthetase, the primers
were 130-bp sense, 5P-GGT GAA CAC CAT CTG
TGA CG-3P ; and 2200-bp antisense, 5P-TAA GCT
CCT GTG AGC TGG GT-3P (the fragment was
2070 bp); for L-actin, the primers were obtained
from Stratagene. The primer pairs were chosen to
yield a product spanning at least one intron^exon
junction and thus ensuring that the PCR product
was mRNA-derived. Ampli¢ed PCR products were
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excised and extracted from an agarose gel as the
major ethidium bromide stained band using a Jetsorb
extraction kit (Genomed). Ampli¢ed DNA fragments
were sequenced with sequanase 2.0 DNA sequencing
kit (Amersham). Nucleic acids were separated on 6%
(w/v) polyacrylamide/8 M-urea gels. The resulting
radiolabeled bands were visualized by exposing the
gel, dried on Whatman 3 MM paper, to Kodak X-
Omat RP ¢lm for 15 h.
2.4. Oligonucleotide treatment of cells
A phosphorothioate oligonucleotide antisense
complementary to human IRF-1 nucleic sequence
was designed to hybridize a 18-bp DNA 5P-UTR
region (394 to 3111 bp; 5P-GTG GAA GAG
GGA AGA AGG-3P) of the IRF-1 mRNA. To de-
termine the potency of this antisense oligonucleotide
to inhibit speci¢cally IRF-1 expression we used as
control an oligonucleotide containing four mis-
matches (5P-GTG AAA GCG GGT AGA TGG-
3P). These oligonucleotides were e⁄ciently trans-
fected into cells using the cationic lipid DOTMA,
which interacts spontaneously with DNA to form a
lipid^DNA complex increasing the cellular uptake.
Oligonucleotide (1 WM) and DOTMA (12 Wg) were
incubated separately in RPMI (100 Wl) for 40 min
and mixed for 15 min to form a lipid^DNA complex.
The mixture was diluted to 1 ml with serum-free
RPMI before addition to monolayer cells grown to
80% con£uence in 6-well plates.
Mycoplasma-free HeLa cells, cultured with RPMI
5% (v/v) fetal calf serum, were washed 3 times with
2 ml of serum-free RPMI prewarmed at 37‡C and
were then transfected either with DOTMA^oligonu-
cleotide complex or DOTMA alone. After incubating
for 3 h, the medium was removed and the cells were
washed twice with RPMI and left for an additional
4 h with type II IFN (500 IU/ml) in RPMI contain-
ing 5% (v/v) fetal calf serum. Cells were collected
by scraping. IRF-1 and STAT-1 expression were
evaluated by measuring protein levels using the
Western blotting assay. Total RNA was prepared
with the TRIzol reagent (from Life Technologies)
and transcription of IFN-induced genes was followed
by RT-PCR.
2.5. Two-dimensional gel electrophoresis
Nuclear protein extracts from interferon-treated
HeLa and HepG2 cells (15 Wg), were analyzed by
two-dimensional non-equilibrium pH gradient elec-
trophoresis (NEPHGE). The ¢rst dimension gel con-
tained 1.2% (v/v) ampholine (pH range 3^10) in the
presence of NP-40 and the gel was run at 400 V
overnight. The second dimension was carried out us-
ing SDS-PAGE (10% gels) and proteins were trans-
ferred onto a nitrocellulose membrane. Western blot
analysis was performed with a commercial polyclonal
antibody against IRF-1 followed by goat anti-rabbit
IgG-HRP and development with reagents for chem-
iluminescence detection.
2.6. Immuno£uorescence
HeLa and HepG2 cells were grown on glass slides
and treated with IFN type II (500 IU/ml) for 4 h.
The cells were washed three times with PBS and ¢xed
for 30 min with 3.7% glutaraldehyde-PBS. The ¢xed
cells were incubated for 1 h at 22‡C with speci¢c
polyclonal IgG (1 Wg/ml). After three washes with
PBS, the cells were incubated for 1 h at 22‡C with
tetramethylrhodamine isocyanate-conjugated anti-
rabbit IgG as a second antibody. The cells were
washed in PBS and ¢xed in MOWIOL (2.4 g of
MOWIOL 4^88 in 6 g of glycerol, 6 ml of water,
12 ml of 0.2 M Tris-HCl, pH 8.5). The £uorescence
was detected with an Olympus BH-2 microscope.
2.7. Nuclear extract preparation and electrophoretic
mobility shift assay (EMSA)
Nuclear extracts were prepared from HepG2 and
HeLa cells by a modi¢cation of the procedure [14].
Monolayer cells were harvested by scraping, washed
in cold phosphate-bu¡ered saline (PBS) and homo-
genized in hypotonic bu¡er A (20 mM HEPES-KOH
pH 7.0, 10 mM KCl, 1 mM MgCl2, 1 mM DTT and
1 mM PMSF). Nuclei were collected by centrifuga-
tion at 2000Ug for 5 min. Nuclear proteins were
extracted from nuclei with 1.2 M KCl, 10% (v/v)
glycerol and 0.1 mM EDTA in bu¡er A. Insoluble
material was removed by centrifugation at 10 000Ug
for 15 min at 4‡C and the supernatants were dialyzed
for 2 h against 100 mM KCl, 20 mM HEPES-KOH
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pH 7.9, 0.1 mM EDTA, 1 mM DTT, 0.25 mM
PMSF and 10% (v/v) glycerol. Protein concentra-
tions were estimated by the Bradford assay (Bio-
Rad).
EMSA was performed by incubating 3 Wg of nu-
clear proteins in binding bu¡er (20 mM HEPES-
KOH pH 7.4, 0.1 mM EGTA, 1 mM MgCl2, 40
mM KCl, 0.5 mM DTT, 4% (v/v) ¢coll and 12 pM
non-speci¢c DNA) for 5 min on ice. Then, an end-
labeled double-stranded oligonucleotide probe (2.5
pM) was added and the reaction mixture was incu-
bated for 15 min at 20‡C. The probe was a synthetic
oligonucleotide containing an IRF-1 sequence found
in the human IDO gene promoter (3455 to 3433:
5P-cta gct AAT TTT GGT TTC AGT TTT CCT Tac
agg t-3P) and previously used in EMSA experiments
[14]. The probe was 5P-end labeled with 15 U of
polynucleotide kinase in the presence of Q [32P]
ATP (3000 Ci/mM, 30 WCi). For competition assays
either a 50-fold excess of unlabeled oligonucleotide
or 0.1 Wg of anti IRF-1 polyclonal antibodies, respec-
tively, were ¢rst added to the mixture for 10 min at
20‡C prior to addition of the labeled probe. Protein^
DNA complexes were fractionated in non-denaturing
5% (w/v) acrylamide gels run in 90 mM Tris-borate
pH 8.0, 2 mM EDTA. The radioactivity present in
the dried gel was detected using the phosphoimager
Storm 840.
3. Results
3.1. Growth inhibition of HepG2 and HeLa
IFN-treated cells
RNase L and 2^5A synthetase are two enzymes of
the 2^5A system strongly implicated in the basal
control of RNA decay [15]. We reported recently
that the HepG2 cell line is completely de¢cient in
RNase L and its mRNA, while 2^5A synthetase is
normally expressed and induced by IFNs [13]. It was
therefore considered of interest to determine whether
this cell line still responds to the antigrowth and
antiviral properties of interferons. To approach this
problem, we determined the e¡ects of interferons on
HepG2 cell growth and [3H]thymidine incorporation
into DNA in comparison with HeLa cells used as a
positive control. As shown in Fig. 1, HepG2 cells
were entirely resistant to the antigrowth e¡ect of
type I and II interferon. As expected, no signi¢cant
inhibition of [3H]thymidine incorporation was de-
tected at interferon concentrations up to 500 IU/ml.
By contrast, HeLa cell growth was inhibited and
500 IU/ml of IFN (I or II) resulted in 65% inhibi-
tion for up to 5 days. This e¡ect was corroborated
by inhibition of the exogenous incorporation of
[3H]thymidine into DNA. At day 5, thymidine incor-
poration was inhibited by 40% with respect to un-
Fig. 1. HepG2 cell growth is unresponsive to interferon. Fol-
lowing a 1-day incubation of HeLa and HepG2 cells with 500
IU/ml of type I or II interferon, cells were numbered and the
incorporation of [3H]thymidine into insoluble materials was
measured after a 24 h labeling period (see Section 2). Inhibition
of cell growth and [3H]thymidine incorporation into DNA are
relative values obtained with cells not treated with interferons.
Values are the average of two replicates. Open and lightly
shaded bars represent HeLa cells treated with type I or II IFN,
respectively. Hatched and dark bars represent HepG2 cells
treated with type I or II IFN, respectively.
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treated HeLa cells while no inhibition of thymidine
incorporation was seen in interferon-treated HepG2
cell. Growth inhibition was observed over a 5-day
period in HeLa cells followed by a 2-fold increase
in cell numbers over the subsequent 48 h.
3.2. Anti-EMCV and anti-VSV action of interferon in
HepG2 and HeLa cells
It has been shown previously that the 2^5A system
is involved in the antipicornavirus e¡ect of IFNs
[8,16^18]. However, this system is neither necessary
nor su⁄cient to inhibit VSV replication [16,19]. It
was considered of interest to compare VSV and
EMCV replication in these cells. The induction of
an antiviral state was investigated in sub-con£uent
cultures of human HeLa and HepG2 cells ¢rst
treated for 16 h with di¡erent concentrations of
type I or II interferon prior to infection with VSV
and EMCV at a multiplicity of infection of 1. Virus
yields were determined 24 h later by plaque assay on
L929 cells. Viral replication was observed to be in-
hibited in a concentration-dependent fashion in
HeLa cells pretreated with type I or II IFN and
the highest virus reduction was obtained with 500
IU/ml. Fig. 2 illustrates these observations: IFN-
treated HepG2 cells were less resistant to VSV and
EMCV infection than IFN-treated HeLa cells used
as control. Interferon (type I or II) reduced EMCV
replication by at least 5 log10 in HeLa cells treated
with 500 IU/ml of IFN in comparison with unstimu-
lated cells. In contrast, no antiviral e¡ect was ob-
served with lower IFNs concentrations in HepG2
cells. There was no signi¢cant di¡erence between
type I and II interferon as regards their anti
EMCV action. As far as anti VSV e¡ect is con-
cerned, HepG2 cells were entirely unprotected from
VSV when treated with type II IFN compared to
HeLa cells which exhibited a 2 log10 reduction in
virus titer. However, HepG2 cells showed less than
Fig. 2. HepG2 cells are resistant to the anti-EMCV and anti-VSV activity of interferons. HeLa (hatched bars) and HepG2 (dark bars)
cell lines were incubated with di¡erent concentrations of type I or II interferon for 16 h and subsequently infected with VSV or
EMCV at a multiplicity of infection of 1 (see Section 2. Virus yields were determined 72 h later by plaque assay on L929 cells. Values
are the average of two replicates.
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a 1 log10 reduction in VSV yield when treated with
type I IFN while a 4 log10 reduction in virus titer was
seen in HeLa cells. It is also interesting to note that
VSV production was far more markedly inhibited by
type I IFN.
We were therefore interested in determining why
this cell line was unable to establish an antiviral state
against both EMCV and VSV lytic viruses. These
observations led us to address the question whether
the impaired antiviral and antiproliferative action is
due to the lack of some interferon-inducible genes
others than RNase L as previously shown [13].
3.3. Induction of transcription of some genes in
HepG2 cells
Several IFN-inducible genes have been put for-
ward as mediators of the antiviral and antiprolifer-
ative action of IFNs [20]. The induction by interfer-
ons of some known genes was therefore studied at
the mRNA level in a comparative manner in HeLa
and HepG2 cells. Total RNA was extracted follow-
ing induction by either type I or II IFN (500 IU/ml)
for 4 h and subjected to RT-PCR. As shown in Fig.
3a, the steady-state mRNA levels were dependent on
the type of interferon. Type I IFN induced mRNA
expression of p56-trptRNA synthetase, 2^5AS, PKR
and 6-16 genes, no signi¢cant di¡erence was seen
between Hela and HepG2 cells. As far as PKR is
concerned, a constitutive and basal mRNA level
was detected in both cell lines. Remarkably, no
type II IFN-induced transcription was found for 6-
16 and 2^5AS and only a low level of mRNA was
detected for p56-trptRNA synthetase. p48-ISGF3Q
was expressed at a low level by both IFNs. The
steady-state mRNA levels of 2^5AS, PKR and 6-16
genes were una¡ected when cells were triggered by
type I IFN in the presence of cycloheximide (not
shown), demonstrating that mRNA expression is
regulated as a primary response to IFN treatment.
This clearly argues for a functional primary response
pathway in HepG2 cells.
In HeLa cells, RNase L, IDO, GBP-2 and iNOS
mRNA level was strongly induced by type II inter-
feron and far less by type I while it was fully im-
paired in HepG2 cells by both types of interferon
(Fig. 3a, left panel). This induction is abolished
when HeLa cells were pretreated with cycloheximide
(50 Wg/ml) (Fig. 3b). We have previously shown that
RNase L and IDO mRNA expression by type I IFN
is also inhibited by cycloheximide [13]. This demon-
strates that the induction of expression is not a pri-
mary response to interferon treatment and that pro-
tein synthesis is required. In this two-step mechanism
of IFNs activity, the protein product of a directly
inducible gene(s) is required to activate a second
set of genes. In the particular case of RNase L
(which is an ubiquitous enzyme even present at low
levels in IFN-untreated cells) its mRNA IFN-inde-
pendent basal level, only detectable by RT-PCR, was
not abrogated by cycloheximide (Fig. 3b, compare
lanes 1 and 3). Nevertheless, both basal and IFN-
induced mRNA were lacking in HepG2.
As IRF-1 has been shown to be implicated in the
expression of some genes i.e. iNOS [21], GBP-2 [22]
and IDO [23], those impaired in HepG2, it was con-
sidered pertinent to determine whether IRF-1
mRNA is normally induced in HepG2 cells. As
shown in the Fig. 3a, IRF-1 mRNA was highly in-
duced by type II interferon and barely by type I in
both HeLa and HepG2 cells and this e¡ect persists
even in the presence of cycloheximide, showing that
IRF-1 expression is a primary response to interferon.
No IRF-1 mRNA level was detected by RT-PCR in
unstimulated cells. Again these observations clearly
demonstrate that the primary response to type I and
II interferon dependent pathways is not impaired in
HepG2 cells.
3.4. Transfection of HeLa cells with an IRF-1
antisense oligonucleotide
To investigate further the critical role of IRF-1
factor in the interferon-inducible expression of
some genes, focusing more particularly on those im-
paired in HepG2 cells, we employed an antisense
oligonucleotide chosen to hybridize to the 5P-un-
translated region (394 to 3111 bp) of human IRF-
1 mRNA. To con¢rm whether this antisense oligo-
nucleotide (394 to 3111 bp) was able to inhibit spe-
ci¢cally IRF-1 in HeLa cells, we examined IRF-1
and STAT-1 at the protein levels. As shown in Fig.
4a, it is observed that IRF-1 protein, strongly in-
duced by type II IFN, was almost completely inhib-
ited by IRF-1 antisense pretreatment. By contrast,
induction of the STAT-1 factor remained una¡ected
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by IRF-1 antisense transfection, demonstrating the
high speci¢city of the target antisense oligonucleotide
for IRF-1 mRNA alone. Moreover, an antisense
control experiment was included in which the se-
quence composition of the oligonucleotide contained
four mismatches (see Section 2). An additional proof
of speci¢city was given by the ine⁄ciency of the con-
trol oligonucleotide to reduce the IRF-1 protein level
(not shown).
We then examined the e¡ect of IRF-1 antisense
oligonucleotide on type II IFN induction of RNase
L, GBP-2 and IDO mRNA levels and observed that
IRF-1 deprived cells were speci¢cally impaired in
IFN induction of the secondary response pathway.
Fig. 3. mRNA levels of RNase L, iNOS, GBP-2, IDO, IRF-1, 6-16, PKR, 2^5AS, p48-ISGF3Q and p56-tRNA synthetase in HeLa
and HepG2 IFN-treated cells. (a) HeLa and HepG2 cells were treated with type I or type II IFN (500 IU/ml) for 4 h before extrac-
tion of total RNA. First strand cDNA was obtained by reverse transcription and the steady-state mRNA level was determined by
PCR using a gene speci¢c pair of sense and antisense oligonucleotides that span an intron-junction of the gene (see Section 2). The
ampli¢ed products were electrophoretically resolved in 1.2% (w/v) agarose gels and revealed by ethidium bromide reagent. Left panel:
comparative mRNA levels of RNase L, IDO, GBP-2, iNOS and IRF-1 in HeLa and HepG2 cells treated with type I and II IFN.
Right panel : up-regulation of p56-tRNA synthetase, 2^5AS, PKR, 6-16, and p48 mRNA expression was observed mainly with type I
IFN in both HeLa and HepG2 cells. The quality of the RNA preparation was investigated using a set of primers speci¢c for the L-ac-
tin gene. (b) HeLa cells were treated with 500 IU/ml of type II IFN for 4 h in the absence or presence of cycloheximide (CHX) at 50
Wg/ml. Levels of mRNA were estimated by RT-PCR as described above.
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Conversely PKR and L2 W-globulin genes remained
una¡ected by the depletion of IRF-1 factor (Fig. 4b).
These results clearly demonstrated that RNase L,
IDO and GBP-2 were dependent on IRF-1 levels,
while PKR and L2 W-globulin, not regulated by
IRF-1, were dependent on a primary response path-
way.
Although IRF-1 was slightly induced by type I
IFN, as shown in the Fig. 5a, no e¡ect of IRF-1
antisense oligonucleotide on the 2^5AS and PKR
mRNA levels was observed when cells were treated
with type I IFN (not shown).
3.5. IRF-1 gene expression, protein synthesis and
DNA binding activity
A recent report has shown that IRF-1 is truncated
in HepG2 cells, impairing expression of IDO [24]. It
was therefore of interest to characterize IRF-1 at its
protein levels. A DNA ampli¢ed fragment of 1355 bp
overlapping the whole IRF-1 cDNA was obtained
from HepG2 and sequenced. The deduced amino
acid sequence from HepG2 cDNA was identical to
the subsequent complete published sequence [25].
As a speci¢c anti-IRF-1 antiserum became avail-
able quantitative and qualitative analyses of IRF-1
were performed after various treatments of cells that
were then processed to prepare nuclear extracts. The
¢rst experiment examined the upregulation and ac-
cumulation of IRF-1 on cell treated with type I or II
IFN for 4 h. As illustrated in Fig. 5a by Western blot
analysis, trace amounts of basal IRF-1 protein were
observed in the absence of IFN-treatment mainly in
HepG2 cells; type I IFN elevated IRF-1 protein level
approximately three-fold, while type II increased syn-
thesis 8^9-fold. The HeLa and HepG2 cells showed
similar levels of protein. These observations corrob-
orate the di¡erence observed in mRNA levels in-
duced by IFN type I and II in both cell lines (com-
pare Fig. 3a and 5a). A kinetic study of protein
synthesis in type II IFN-treated cells after 2, 4, 6, 8
and 16 h indicated that IRF-1 protein was mainly
induced between 2 and 6 h for HepG2 and between
2 and 8 h for HeLa cells. This light di¡erence in the
abundance of the protein could be due to a cell-type
speci¢city. In agreement with previous reports
[13,26], IRF-1 migrated with an apparent molecular
weight of 56 kDa. The complete cDNA sequence and
Fig. 4. E¡ects of IRF-1 antisense oligonucleotide on IRF-1 pro-
tein levels (a) and on IRF-1-dependent mRNA levels (b) of
RNase L, IDO, GBP-2 in type II IFN treated-HeLa cells. (a)
A Western blot was performed with protein extracts (40 Wg/
lane) from: lane 1, untreated HeLa cells ; lane 2, cells treated
with type II IFN (500 IU/ml) for 4 h; lane 3, cells treated with
the cationic lipid DOTMA then induced with IFN; lane 4, cells
treated with the DOTMA-antisense oligonucleotide complex
then induced with IFN. The speci¢city of the IRF-1 antisense
oligonucleotide was demonstrated by comparative detection of
IRF-1 and STAT-1 proteins with speci¢c polyclonal antibodies
(from Santa Cruz). Bound antibodies were revealed by chemilu-
minescence using HRP-anti rabbit polyclonal antibodies and
the ECL detection kit. (b) mRNA levels, detected by RT-PCR,
in HeLa cells treated with or without IRF-1 antisense and in-
duced by IFN (500 IU/ml for 4 h). Ampli¢ed products were
separated by electrophoresis in 1.2% (w/v) agarose gel and
stained with ethidium bromide. Lanes 1^4 are the same experi-
mental conditions as in a.
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the apparent molecular weight indicated that IRF-1
was not truncated in HepG2 cells.
It has been suggested that kinases play a role in
IRF-1 activation and di¡erent levels of IRF-1 phos-
phorylation correlated with its DNA-binding activ-
ities [26]. We investigated whether IRF-1 phospho-
rylation was impaired in nuclear extracts of HepG2
cells treated for 2 h with type II IFN (500 IU/ml).
Two-dimensional separation by isoelectric focusing
and SDS-PAGE resolved IRF-1 into two major iso-
forms (pI 4.8^5.5). The proportion of each isoform
remained approximately the same in both HeLa and
HepG2 cell lines (Fig. 6). It is therefore unlikely that
di¡erential phosphorylation can account for the lack
of expression of the IRF-1-dependent inducible genes
described above.
The intracellular distribution of IRF-1 was ex-
plored by comparative immuno£uorescence analysis
on untreated or IFN type II treated cells for 4 h.
HeLa and HepG2 cells were grown on a solid sup-
port, ¢xed and treated with commercial IRF-1 poly-
clonal antibodies. Binding was revealed by an anti-
IgG rabbit antibody conjugated to tetramethylrho-
damine isothiocyanate. No di¡erence was seen be-
tween these two cell lines. As shown in the Fig. 7,
the £uorescence was essentially located in the nuclei
in agreement with our previous biochemical charac-
terization of IRF-1 in the nuclear extract shown in
the Fig. 5.
It is well established that type II IFN treatment of
cells rapidly activates transcription factor IRF-1,
which recognized a speci¢c DNA motif [11]. To in-
vestigate whether IRF-1 DNA-binding activity is
preserved in HepG2 cells, we made use of an oligo-
nucleotide probe derived from the human IDO pro-
moter gene and previously used in IRF-1 DNA bind-
ing studies [14]. As illustrated in the Fig. 8, three
major DNA retarded bands A, B and C were ob-
served in both IFN-treated HeLa and HepG2 cells.
Except the presence of some minor bands seen in
HeLa nuclear extract (denoted by the arrows), no
signi¢cant di¡erence was observed between these
two cell lines (compare lane 1 and 2). Bands A, B
and C were strongly attenuated in IFN-untreated
HepG2 cells, attesting, as previously shown in Fig.
5a, that unstimulated HepG2 cells contained very
low level of IRF-1 protein (lane 3). Protein binding
to this probe was speci¢c because addition of IRF-1
speci¢c polyclonal antibodies, prior addition of the
labeled probe, partially competed these major com-
plexes (lane 4). In addition, an excess of the unla-
beled probe (50-fold excess) completely abolished the
protein^DNA binding (lane 5). In view of these re-
Fig. 5. IRF-1 protein levels in interferon-treated HeLa and
HepG2 cells. (a) IRF-1 protein levels induced by type I or II
interferon (500 IU/ml) for 4 h. Nuclear extracts (20 Wg in each
lane) were analyzed in Western blot assay for detection of IRF-
1 protein with rabbit polyclonal antibody and chemilumines-
cence with a second goat anti-rabbit IgG peroxidase antibody.
(b) Kinetics of induction of IRF-1 protein in Hela and HepG2
cells by type II IFN for 2, 4, 6, 8 and 16 h. The relative inten-
sity of the signal given by ECL detection and shown above,
was quanti¢ed by autoradiogram scanning. Empty bars are for
HeLa cells and hatched bars for HepG2 cells, zero is for un-
treated cells.
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sults, it was concluded that the speci¢c binding com-
plexes identi¢ed in HepG2 cells by EMSA contained
an active IRF-1 DNA binding protein. The multiple
bands seen in this experiment and found also by
others [14,27] could correspond to a monomeric
and a dimeric complex form. Taking together these
experiments demonstrate that the transcription factor
IRF-1 is fully functional in HepG2 cells and that a
missing link occurs in the overall secondary JAK/
STAT pathway.
Fig. 7. Immuno£uorescence location of IRF-1 in HeLa and HepG2 cells treated with or without type II IFN (500 IU/ml for 4 h).
Cells were ¢xed and incubated for 1 h at 22‡C with IRF-1 speci¢c rabbit polyclonal IgG antibodies (1 Wg/ml). These bound antibodies
were revealed with a tetramethylrhodamine isocyanate-conjugated anti-rabbit IgG, and detected by £uorescence microscopy. Label im-
muno£uorescent images of HeLa (upper panel) and HepG2 cells (lower panel) demonstrated the accumulation of IRF-1 in nuclei of
IFN-treated cells (+). Untreated cells (3) were used as negative controls.
Fig. 6. Two-dimensional gel analysis of IRF-1 present in nuclear protein extracts from IFN-treated HeLa and HepG2 cells. Cells were
treated with type II IFN (500 IU/ml for 4 h) and nuclear extracts were prepared as described in Section 2. Proteins (15 Wg estimated
with the Bradford assay) were separated in non-equilibrium pH gel electrophoresis (NEPHGE) at 400 V overnight, using 1.2% (v/v)
ampholine with a pH scale of 3.0^10.0). The second dimension is 10% SDS/PAGE. The positions of the proteins markers and their
sizes in kDa are indicated. The resulting gel is transferred to a nitrocellulose membrane and IRF-1 isoform detection was performed
with IRF-1 speci¢c polyclonal antibodies. Bound antibodies were revealed by chemiluminescence (ECL, Amersham) with a second
goat anti-rabbit IgG-HRP.
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4. Discussion
The complexity of the cellular process triggered by
type I and II IFN is mainly due to the involvement
of a large repertoire of induced proteins of ill-de¢ned
function expressed by the two overlapping response
pathways. Our results show that the hepatoma cell
line HepG2 is unresponsive to both types of interfer-
on in correlation with altered expression of some
induced genes. RNase L, IDO, iNOS and GBP-2
genes, normally expressed as a secondary response
to IFNs, are no longer inducible. In addition, more
recently, it was demonstrated that CIITA transcrip-
tion factor was also lacking in this cell line [28]. We
demonstrated, however, that primary response JAK/
STAT pathway is functional as type I mainly induces
PKR, 2^5AS, p48-ISGF3Q and p56-trptRNA syn-
thase mRNA expression and type II triggers the ex-
pression of IRF-1 gene.
Evidence for IRF-1 implication in the induction of
type II interferon genes has been provided for iNOS
[21] and GBP-2 genes [22] using mouse embryonic
cells with a null mutation in the IRF-1 gene and
for IDO gene in cells transiently transfected with
IRF-1 cDNA [29]. These observations are consistent
with our results presented here and obtained by
transfection of HeLa cells with an IRF-1 antisense
oligonucleotide. These results lend further support to
the proposal that the absence of IRF-1 alone is suf-
¢cient to prevent IFN-expression of RNase L, IDO
and GBP-2 mRNA. RNase L (which is a pivotal
enzyme in the interferon system) has not been pre-
viously studied at the regulation level, probably be-
cause its mRNA levels are low, hardly detectable on
Northern blot. Unlike IDO, GBP-2 and iNOS genes,
RNase L was noted to be regulated at a basal and
IFN-induced level of transcription. We show that,
unlike the IFN-induced level, the low constitutive
basal mRNA level was una¡ected by the presence
of cycloheximide, both levels of expression noted to
be lacking in HepG2 cells. The use of antisense IRF-
1 transfected cells provides supplementary informa-
tion concerning the role played by IRF-1 in the ex-
pression of the RNase L intact gene in situ. Thus,
inhibiting IRF-1 accumulation in HeLa cells causes
complete inhibition of type II IFN RNase L mRNA
expression at both basal and induced levels. This
establishes a link between IRF-1 and RNase L and
could explain their similar implication in pro-apop-
totic [22,30] and antiviral activity [30,31]. As the anti-
sense oligonucleotide shows transient inhibitory ef-
fects, we were unable to correlate IRF-1 activity
with its expected biological antiviral and antiprolifer-
ative properties. Total lack of IRF-1 in vivo causes a
de¢ciency in the EMCV antiviral activity of interfer-
Fig. 8. Binding of IRF-1 to the IDO promoter analyzed by
electrophoretic mobility shift assay (EMSA). Nuclear extracts
were prepared either from HeLa and HepG2 cells treated with
type II IFN (500 IU/ml for 4 h) (lanes 1 and 2, respectively) or
unstimulated HepG2 cells (lane 3). Nuclear proteins (3 Wg) were
used in each binding reaction with 32P-labeled double-stranded
oligonucleotide (2.5 pM). Competition experiments were real-
ized with IFN-treated HepG2 cells, by using either an antise-
rum raised against IRF-1 (lane 4) or a 50-fold molar excess of
unlabeled oligonucleotide (lane 5). The radioactivity present in
the dried gel was detected by PhosphorImage analysis using a
Storm 840 apparatus.
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on while mice, unlike HepG2 cells, remained pro-
tected against VSV [31]. This di¡erence could be at-
tributed to a de¢ciency of other genes in HepG2
cells.
A previous report has shown that IRF-1 was un-
stable and truncated in HepG2 cells in correlation
with the lack of mRNA IDO expression [24]. Here
we clearly showed that IRF-1 protein retained its
normal size. The reasons for this discrepancy re-
mained unknown, but could be due to a degradation
of the protein by proteases during the extraction
procedures. Our data show unequivocally that IRF-
1 is IFN-induced and functional in HepG2 cells. A
block in transcriptional complex formation between
IRF-1 and ISRE-like sequences by an unknown re-
pressor may be involved in HepG2 cells. Neverthe-
less, band shift assays with ISRE-like sequences and
IRF-1 from HeLa and HepG2 nuclear extracts did
not show any di¡erences. It has been shown previ-
ously that IRF-1 activity can be repressed by other
proteins belonging to the IRF group. Some of these
repressor molecules, such as IRF-2, ICSAT and
ICSBP bind to the ISRE-like sequence or the IRF-
1 factor and prevent IRF-1-dependent gene induc-
tion [32^34]. As shown previously, low levels of the
IRF-2 inhibitor are detected in HepG2 and Western
blot analysis indicates that there is no substantial
di¡erence between HeLa and HepG2 cells [13].
Moreover, ICSBP and ICSAT proteins, known to
be expressed in lymphocytes and macrophages line-
ages only, are not detectable in HepG2 (not shown).
An alternative mechanism for the inhibition of inter-
feron activities and thereby IRF-1 function, involves
viral gene products. This is particularly attractive in
view of the recent ¢ndings that hepatitis B virus and
adenovirus antigens may disrupt the expression of
some IFN-inducible genes [35]. The antagonistic re-
lationship between the IFN system and viruses is
universal and viruses employ strategies to escape
IFN antiviral e¡ects. The X gene product, encoded
by the hepatitis B virus and known to alter transcrip-
tion by targeting the DNA-basic region of some
transcription factors [36] was not found in HepG2
cells (not shown). Similarly, we can assume that the
E1A antigen is not implicated since this molecule
inhibits both type I and II interferon-inducible genes
[37].
The regulation of this set of genes, impaired in
HepG2 cells, by an unknown transcription factor is
emerging. The presence of GAS and two ISRE se-
quences in IDO, iNOS and probably other pro-
moters could lead to the formation of a transcription
complex including STAT, IRF-1 and an additional
unknown transcription factor. A previous study has
shown that cells transfected with an IRF-1 cDNA
and constitutively expressing high levels of IRF-1
did not show enhanced IDO mRNA synthesis
when treated with type II IFN in the presence of
cycloheximide [12]. This ¢nding suggests that addi-
tional cycloheximide-sensitive transcription factor,
di¡erent from IRF-1, is required for a correct expres-
sion of defective HepG2 genes. Taken together, these
observations give further support to the notion that a
cooperative transcription factor is lacking in these
hepatocarcinoma cells. This tumor model system
can therefore be an interesting tool to study the reg-
ulation of expression of the IRF-1-dependent genes.
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